Opus Genetics Inc
NASDAQ:IRD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Luye Pharma Group Ltd
HKEX:2186
|
CN |
|
Glosel Co Ltd
TSE:9995
|
JP |
|
G
|
Global Battery Metals Ltd
OTC:REZZF
|
CA |
Opus Genetics Inc
Total Equity
Opus Genetics Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Opus Genetics Inc
NASDAQ:IRD
|
Total Equity
$15.3m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-2%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Equity
$81.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Equity
$18.5B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
3%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Equity
$86.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Equity
$52.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Equity
$26.5B
|
CAGR 3-Years
36%
|
CAGR 5-Years
36%
|
CAGR 10-Years
6%
|
|
Opus Genetics Inc
Glance View
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 14 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. Its pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and being evaluated in a Phase I/II open-label, dose-escalation trial, with advancing early data. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See Also
What is Opus Genetics Inc's Total Equity?
Total Equity
15.3m
USD
Based on the financial report for Dec 31, 2025, Opus Genetics Inc's Total Equity amounts to 15.3m USD.
What is Opus Genetics Inc's Total Equity growth rate?
Total Equity CAGR 10Y
-2%
Over the last year, the Total Equity growth was -40%. The average annual Total Equity growth rates for Opus Genetics Inc have been -31% over the past three years , and -2% over the past ten years .
